May 1st 2024
The combination of pembrolizumab, trastuzumab, and chemotherapy showed significant improvement in overall survival vs placebo in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Becerra Shares Treatment Considerations in 2 Gastrointestinal Case Studies
April 10th 2018Carlos Becerra, MD, recently shared the treatment considerations and decisions he makes when treating patients with metastatic colorectal cancer and hepatocellular carcinoma. Becerra, a medical oncologist at Texas Oncology, Baylor Charles A. Sammons Cancer Center, explained his treatment decisions based on 2 case scenarios during a <em>Targeted Oncology </em>live case-based peer perspectives presentation.
Read More
Top-Line Results Show Ramucirumab Improves Survival in Second-Line HCC
April 10th 2018Overall survival was extended in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein (AFP) who received second-line treatment with ramucirumab (Cyramza) versus placebo, according to findings from the phase III REACH-2 trial.
Read More
Sanjeevani Arora Receives Cancer Research Grant from Department of Defense
April 6th 2018The US Department of Defense has selected Sanjeevani Arora, PhD, as the recipient of the Peer Reviewed Cancer Research Program Career Development award and grant for fiscal year 2017. The grant will be used to fund clinical efforts benefiting both military and civilian patients.
Read More
T-VEC Injections Safe in Patients with Advanced-Stage Liver Metastases
March 29th 2018According to early results of an ongoing early-phase study presented at the 2018 Society of Interventional Radiology Annual Scientific Meeting, image-guided injections of talimogene laherparepvec immunotherapy (T-VEC, Imylgic) were deemed tolerable in patients with advanced-stage liver metastases.
Read More
Bendell Takes the Helm as Chief Development Officer at Sarah Cannon
March 22nd 2018Internationally renowned expert, Johanna C. Bendell, MD, has been promoted to chief development officer at Sarah Cannon. Her title responsibilities include developing and expanding physician, site, and Pharma relationships across the Sarah Cannon Network, thereby expanding the organization’s efforts to bring more qualitative treatment options to its patients.
Read More
SIRT Better Tolerated Than Sorafenib in Patients With Unresectable HCC
March 19th 2018Selective internal radiation therapy with yttrium-90 resin microspheres was better tolerated compared with sorafenib in patients with advanced unresectable hepatocellular carcinoma, However, findings from the phase III SARAH trial did not improve rates of overall survival or progression-free survival. A radiotherapy approach was compared with this targeted therapy in the SARAH trial.
Read More
Marshall Highlights Treatment Options for Left-Sided mCRC
March 16th 2018John Marshall, MD, recently discussed the treatment options and decisions he makes when treating patients with metastatic colorectal cancer. Marshall explained his treatment decisions based on 2 case scenarios during a <em>Targeted Oncology </em>live case-based peer perspectives presentation.
Read More
Edward Wolin to Direct Neuroendocrine Center at Tisch Cancer Institute
March 14th 2018Edward M. Wolin, MD, has been named the director of the Center for Carcinoid and Neuroendocrine Tumors at The Tisch Cancer Institute of Mount Sinai Health System. He will also serve as a professor of medicine (hematology and medical oncology) at the Icahn School of Medicine at Mount Sinai.
Read More